Cargando…

Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept

Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergantim, Rui, Peixoto da Silva, Sara, Polónia, Bárbara, Barbosa, Mélanie A. G., Albergaria, André, Lima, Jorge, Caires, Hugo R., Guimarães, José E., Vasconcelos, M. Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690807/
https://www.ncbi.nlm.nih.gov/pubmed/36430163
http://dx.doi.org/10.3390/ijms232213686
_version_ 1784836885374304256
author Bergantim, Rui
Peixoto da Silva, Sara
Polónia, Bárbara
Barbosa, Mélanie A. G.
Albergaria, André
Lima, Jorge
Caires, Hugo R.
Guimarães, José E.
Vasconcelos, M. Helena
author_facet Bergantim, Rui
Peixoto da Silva, Sara
Polónia, Bárbara
Barbosa, Mélanie A. G.
Albergaria, André
Lima, Jorge
Caires, Hugo R.
Guimarães, José E.
Vasconcelos, M. Helena
author_sort Bergantim, Rui
collection PubMed
description Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect biomarkers of MRD in EVs isolated from MM patient samples at diagnosis and remission and compare the MRD-associated content between BM and PB EVs. EVs were isolated by size-exclusion chromatography, concentrated by ultrafiltration, and characterized according to their size and concentration, morphology, protein concentration, and the presence of EV-associated protein markers. EVs from healthy blood donors were used as controls. It was possible to isolate EVs from PB and BM carrying MM markers. Diagnostic samples had different levels of MM markers between PB and BM paired samples, but no differences between PB and BM were found at remission. EVs concentration was lower in the PB of healthy controls than of patients, and MM markers were mostly not detected in EVs from controls. This study pinpoints the potential of PB EVs from MM remission patients as a source of MM biomarkers and as a non-invasive approach for monitoring MRD.
format Online
Article
Text
id pubmed-9690807
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96908072022-11-25 Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept Bergantim, Rui Peixoto da Silva, Sara Polónia, Bárbara Barbosa, Mélanie A. G. Albergaria, André Lima, Jorge Caires, Hugo R. Guimarães, José E. Vasconcelos, M. Helena Int J Mol Sci Article Monitoring measurable residual disease (MRD) is crucial to assess treatment response in Multiple Myeloma (MM). Detection of MRD in peripheral blood (PB) by exploring Extracellular Vesicles (EVs), and their cargo, would allow frequent and minimally invasive monitoring of MM. This work aims to detect biomarkers of MRD in EVs isolated from MM patient samples at diagnosis and remission and compare the MRD-associated content between BM and PB EVs. EVs were isolated by size-exclusion chromatography, concentrated by ultrafiltration, and characterized according to their size and concentration, morphology, protein concentration, and the presence of EV-associated protein markers. EVs from healthy blood donors were used as controls. It was possible to isolate EVs from PB and BM carrying MM markers. Diagnostic samples had different levels of MM markers between PB and BM paired samples, but no differences between PB and BM were found at remission. EVs concentration was lower in the PB of healthy controls than of patients, and MM markers were mostly not detected in EVs from controls. This study pinpoints the potential of PB EVs from MM remission patients as a source of MM biomarkers and as a non-invasive approach for monitoring MRD. MDPI 2022-11-08 /pmc/articles/PMC9690807/ /pubmed/36430163 http://dx.doi.org/10.3390/ijms232213686 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bergantim, Rui
Peixoto da Silva, Sara
Polónia, Bárbara
Barbosa, Mélanie A. G.
Albergaria, André
Lima, Jorge
Caires, Hugo R.
Guimarães, José E.
Vasconcelos, M. Helena
Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept
title Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept
title_full Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept
title_fullStr Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept
title_full_unstemmed Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept
title_short Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept
title_sort detection of measurable residual disease biomarkers in extracellular vesicles from liquid biopsies of multiple myeloma patients—a proof of concept
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690807/
https://www.ncbi.nlm.nih.gov/pubmed/36430163
http://dx.doi.org/10.3390/ijms232213686
work_keys_str_mv AT bergantimrui detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept
AT peixotodasilvasara detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept
AT poloniabarbara detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept
AT barbosamelanieag detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept
AT albergariaandre detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept
AT limajorge detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept
AT caireshugor detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept
AT guimaraesjosee detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept
AT vasconcelosmhelena detectionofmeasurableresidualdiseasebiomarkersinextracellularvesiclesfromliquidbiopsiesofmultiplemyelomapatientsaproofofconcept